Every Peritia product is a pre-vetted slice of our 4,000+ specialist network. Match to the discipline, scope to the problem, staff in under 48 hours.
The protocol depth your program needs without the hiring cycle. Clinical Development, Clinical Operations, Biostatistics, Medical Writing, and a 4,000+ CRA field-monitoring network — matched by therapeutic area and phase.
Explore Clinical →Protocol design, study operations, vendor strategy — from early phase through pivotal.
Statistical strategy, SAP, programming, PK/PD, survival models. Depth by therapeutic area.
Protocols, CSRs, IBs, safety narratives. Ex-industry writers with TA-specific fluency.
4,000+ vetted CRAs across 20 countries. Risk-based monitoring, specialty therapeutic areas.
Ex-agency specialists on deck. Regulatory strategy, global submissions, CMC/quality, and agency liaison from people who've been inside the room at FDA, EMA, PMDA, and MHRA.
Explore Regulatory →Integrated development & filing strategy, agency interaction plans, briefing documents.
Submission leadership, eCTD compilation, scientific writing, validation, response management.
Ex-FDA, ex-EMA, ex-PMDA specialists. Type B/C meetings, pre-IND, EOP2, pre-BLA.
Process development, analytical strategy, GMP, comparability, tech transfer expertise.
The value story that earns reimbursement. HEOR, HTA strategy (NICE, G-BA, HAS, CADTH), real-world evidence, and value dossier development — for payers who don't take approval as proof.
Explore Evidence →Economic models, budget impact, PRO strategy, indirect comparisons, meta-analyses.
NICE, G-BA, HAS, CADTH, PBAC — multi-market HTA planning and submission leadership.
RWD study design, data acquisition, analytics, regulatory-grade RWE for labeling.
AMCP, global value dossiers, payer-ready evidence packages, core value propositions.
Launch planning, medical affairs infrastructure, market access, and brand strategy from people who've been behind the counter on successful launches. The commercial readiness your approval depends on.
Explore Commercial →Integrated launch readiness, critical path tracking, functional plan orchestration.
MSL strategy, KOL engagement plans, publication strategy, medical information.
Payer strategy, account management, contracting, GPO and IDN navigation.
Positioning, messaging architecture, commercial opportunity assessment.
The boardroom-level brain you don't need full-time. Portfolio shaping, investor readiness, pipeline strategy, and commercial due diligence from operators who have run these functions inside.
Explore Strategy →Asset prioritization, TA focus decisions, pipeline trade-off modeling, resource allocation.
S-1 drafting support, board materials, banker pitch narrative, diligence response.
Pipeline shaping, TPP development, go/no-go frameworks, optionality analysis.
Commercial and scientific diligence for BD, in-licensing, M&A.
When fractional becomes a full-time answer. Executive search for C-suite biotech roles, interim leadership, direct placement, and board advisors — drawn from the same pre-vetted network that powers every other product.
Explore Talent →CMO, CSO, CDO, Head of Clinical, Head of Reg, Head of Commercial — retained search.
Functional interim leaders — CMO, Head of Clin Ops, Head of Regulatory — seated in days.
Permanent placement in specialist and senior roles across life sciences disciplines.
Independent directors, scientific advisors, specialty board committees.
The match is free. The 48-hour promise is real. The first conversation is with a human who has been through this before.